Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P499: Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2

ECCO '19 Copenhagen

Year: 2019
Authors:

E. V. LoftusJr1, W. J. Sandborn2, D. Wolf3, S. Danese4, J. Chen5, X. Yao5, K. Kisfalvi*5, S. Vermeire6

1Mayo Clinic College of Medicine, Rochester, USA, 2University of California San Diego, La Jolla, USA, 3Atlanta Gastroenterology Associates, Atlanta, USA, 4Humanitas University, Milan, Italy, 5Takeda Development Center Americas Inc., Cambridge, USA, 6University Hospitals Leuven, Leuven, Belgium

P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

R. D. Cohen1, F. Bhayat2, A. Blake2, S. Travis*3

1University of Chicago Medicine, Department of Medicine, Inflammatory Bowel Disease Center, Chicago, USA, 2Takeda Pharmaceuticals International Co., Cambridge, USA, 3Oxford University Hospitals NHS Foundation Trust, Translational Gastroenterology Unit, Oxford, UK

P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Lissner*1, B. Jessen1,2, E. Sonnenberg1, M. Schumann1, F. Schmidt1, Y. Rodriguez Sillke1, B. Siegmund1

1Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Department for Medicine (Gastroenterology, Infectious diseases, Rheumatology), Berlin, Germany, 2Berlin Institute of Health, Berlin, Germany

P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Magro*1,2, S. Lopes1, M. Silva1, R. Coelho1, F. Portela3, D. Branquinho3, L. Correia4, S. Fernandes4, M. Cravo5, P. Caldeira6, H. Sousa6,7, M. Patita8, P. Lago9, J. Ramos10, J. Afonso2, I. Redondo11, P. Machado11, G. Philip12, J. Lopes2, F. Carneiro2,13

1Centro Hospitalar São João, Gastrenterology, Porto, Portugal, 2Faculdade de Medicina, Universidade do Porto, Pharmacology, Porto, Portugal, 3Centro Hospitalar Universitário de Coimbra, Gastrenterology, Coimbra, Portugal, 4Centro Hospitalar Lisboa Norte, Gastrenterology, Lisboa, Portugal, 5Hospital Beatriz Ângelo, Gastrenterology, Loures, Portugal, 6Centro Hospitalar Universitário do Algarve, Gastrenterology, Faro, Portugal, 7Universidade do Algarve, Faro, Portugal, 8Hospital Garcia de Orta, Gastrenterology, Almada, Portugal, 9Centro Hospitalar do Porto, Gastrenterology, Porto, Portugal, 10Centro Hospitalar Lisboa Central, Gastrenterology, Lisboa, Portugal, 11MSD Portugal, Medical Affairs, Paço de Arcos, Portugal, 12Merck and Co., Inc., Kenilworth, NJ, USA, 13IPATIMUP, i3S‐Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal

P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Biemans*1, J. van der Woude2, G. Dijkstra3, A. van der Meulen-de Jong4, B. Oldenburg5, N. de Boer6, M. Löwenberg7, N. Srivastava8, J. Jansen9, R. West10, A. de Vries2, J. Haans11, M. Pierik11, F. Hoentjen12

1Radboudumc/MUMC+, Nijmegen, The Netherlands, 2Erasmus MC, Rotterdam, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands, 4Leiden University Medical Centre, Leiden, The Netherlands, 5University Medical Centre Utrecht, Utrecht, The Netherlands, 6Amsterdam University Medical Centre, VU, Amsterdam, The Netherlands, 7Amsterdam University Medical Centre, AMC, Amsterdam, The Netherlands, 8Haaglanden MC, the Hague, The Netherlands, 9Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands, 10Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands, 11Maastricht University Medical Centre, Maastricht, The Netherlands, 12Radboudumc, Nijmegen, The Netherlands

P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Carbonell1, J. Kane1, M. Omer1, A. Odouri Ochieng1, M. Pinder1, R. McKay1, J. Hamlin1, C. Selinger*1

1Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, UK

P505: Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Iborra*1, B. Beltrán1, A. Fernández2, A. Gutiérrez3, B. Antolín4, J. M. Huguet5, R. de Francisco6, O. Merino7, D. Carpio8, S. García López9, F. Mesonero10, M. Mínguez11, R. Ferreiro12, A. Y. Carbajo13, M. Rivero14, M. Chaparro15, M. C. Piñero-Pérez16, D. Monfort i Miquel17, L. Bujanda18, M. F. García-Sepulcre19, A. Martín-Cardona20, F. Cañete21, C. Taxonera22, M. Sierra-Ausin23, J. Á. Ferrer-Rosique24, M. D. Martín-Arranz25, C. González-Muñosa26, N. Manceñido-Marcos27, I. Rodríguez-Lago28, E. Iglesias-Flores29, A. Forés-Bosch30, M. Navarro-Llavat31, M. Calafat32, R. E. Madrigal-Domínguez33, L. Ramos34, M. Arroyo35, D. Busquets36, R. Lorente37, E. Saiz-Arnau38, A. Hernández-Camba39, V. Jair-Morales40, C. Paredes41, M. Van Domselaar42, D. Hervás43, A. Cañada-Martínez43, P. Nos43

1Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital General Universitario de Alicante, Alicante, Spain, 4Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 5Hospital General Universitario de Valencia, Valencia, Spain, 6Hospital Universitario Central de Asturias, Oviedo, Spain, 7Hospital Universitario Cruces, Barakaldo, Spain, 8Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 9Hospital Universitario Miguel Servet, Zaragoza, Spain, 10Hospital Universitario Ramón y Cajal, Madrid, Spain, 11Hospital Clínico Universitario de Valencia, Valencia, Spain, 12Hospital Universitario de Santiago, Santiago de Compostela, Spain, 13Hospital Universitario Río Hortega, Valladolid, Spain, 14Hospital Universitario Marqués de Valdecilla, Santander, Spain, 15Hospital Universitario La Princesa, Madrid, Spain, 16Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 17Consorci Sanitari de Terrassa, Terrassa, Spain, 18Hospital Universitario Donostia, Donostia-San Sebastián, Spain, 19Hospital General Universitario de Elche, Elche, Spain, 20Hospital Mutua de Terrassa, Terrassa, Spain, 21Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 22Hospital Universitario Clínico San Carlos, Madrid, Spain, 23Complejo Asistencial Universitario de León, León, Spain, 24Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, 25Hospital Universitario La Paz, Madrid, Spain, 26Hospital Santa Creu i Sant Pau, Barcelona, Spain, 27Hospital Universitario Infanta Sofía, Madrid, Spain, 28Hospital Universitario de Galdakao, Galdakao, Spain, 29Hospital Universitario Reina Sofía, Córdoba, Spain, 30Hospital General Universitario de Castellón, Castellón, Spain, 31Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, 32Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 33Complejo Hospitalario de Palencia, Palencia, Spain, 34Hospital Universitario de Canarias, Las Palmas, Spain, 35Hospital Central Universitario Lozano Blesa, Zaragoza, Spain, 36Hospital Universitario de Girona Dr J. Trueta, Girona, Spain, 37Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 38Hospital Universitari Arnau de Vilanova, Lleida, Spain, 39Hospital Universitario Nuestra Sra. de la Candelaria, Tenerife, Spain, 40Hospital General de Granollers, Granollers, Spain, 41Hospital Universitario Doctor Peset, Valencia, Spain, 42Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain, 43Hospital Universitario y Politécnico La Fe, Valencia, Spain

P506: Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Tzivinikos*1, J. Jeng2, S. Nevitt2, C. Baillie1, S. Subramanian3, M. Auth1

1Alder Hey Children's Hospital, Liverpool, UK, 2University of Liverpool, School of Medicine, Liverpool, UK, 3Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK

P507: Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Viazis*1, E. Tsoukali1, M. Galanopoulos1, C. Pontas1, G. Karampekos1, G. Filippidis1, O. Giouleme2, G. Theocharis3, M. Tzouvala4, E. Archavlis1, A. Christidou1, G. J. Mantzaris1

1Evangelismos Hospital, Gastroenterology Department, Athens, Greece, 22nd Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokrateion Hospital, Gastroenterology – Hepatology Department, Thessaloniki, Greece, 3University Hospital of Patras, Gastroenterology Department, Patras, Greece, 4Nikaia General Hospital, Gastroenterology Department, Athens, Greece

P508: Does corticosteroid therapy affect prognosis in inflammatory bowel disease patients hospitalised with Clostridium difficile infection?

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Bar Yoseph1,2, H. Daoud3, D. Ben Hur1, Y. Chowers1,2, M. Waterman*1,2

1Rambam Health Care Campus, Institute of Gastroenterology, Haifa, Israel, 2The Technion- Israel Institute of Technology, B. Rappaport Faculty of Medicine, Haifa, Israel, 3Rambam Health Care Campus, Department of Internal Medicine H, Haifa, Israel

P509: Long-term outcomes of adalimumab in patients with Crohn’s disease: Can a doubled dose of adalimumab improve outcomes?

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Kanazawa*1, K. Yokoyama1, Y. Matsumoto1, K. Kawagishi1, M. Mukae1, M. Kubota1, K. Kobayashi1, W. Koizumi1

1Kitasato University School of Medicine, Gastroenterology, Sagamihara, Japan

P510: Infliximab in the very young: it is all about the dosing – a multi-centre study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Jongsma*1, D. Winter1, H. Huynh2, L. Norsa3, S. Hussey4, K-l. Kolho5, J. Bronsky6, A. Assa7, S. Cohen8, R. Lev-Tzion9, S. van Biervliet10, T. de Meij11, D. Shouval12, E. Wine2, V. Wolters13, A. Christiaens14, C. Martinez-Vinson15, L. de Ridder1

1ErasmusMC-Sophia Children's Hospital, Pediatric Gastroenterology, Rotterdam, The Netherlands, 2Edmonton Pediatric IBD Clinic, Pediatric Gastroenterology and Nutrition, Edmonton, Canada, 3Hopital Necker-enfants-malades, Pediatric Gastroenterology, Paris, France, 4Our Lady's Children's Hospital and RSCI, Pediatric Gastroenterology, Dublin, Ireland, 5Children's Hospital Helsinki, Pediatric Gastroenterology, Helsinki, Finland, 6University Hosptital Motol, Pediatric Gastroenterology, Praque, Czech Republic, 7Schneider Chidren's Hospital, Pedriatric Gastroentrolgy, Tel Aviv, Israel, 8Dana-Dwek Children's Hospital, Pediatric Gastroenterology, Israel, Israel, 9Shaare Zedek Medical Center, Pediatric Gastroenterology, Jerusalem, Israel, 10Universitair Ziekenhuis Gent, Pediatric Gastroenterology, Gent, Belgium, 11VU Medical Center, Pediatric Gastroenterology, Amsterdam, The Netherlands, 12Sheba Medical Center, Pediatric Gastroenterology, Tel Aviv, Israel, 13Utrecht Medical Center, Wilhelmina Children's Hospital, Pediatric Gastroenterology, Utrecht, The Netherlands, 14Universitair Kinderziekenhuis Brussel, Pediatric Gastroenterology, Brussel, Belgium, 15Hopital Robert Debré, Pediatric Gastroenterology, Paris, France

P511: Radiological outcomes in perianal fistulising Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Lee*1, M. Kamm2, S. Bell2, M. Lust2, S. Brown2, E. Wright2, W. Connell2, E. Yong3, N. Ding2

1St Vincent's Hospital, Melbourne, Clinical School, Fitzroy, Australia, 2St Vincent's Hospital, Melbourne, Gastroenterology, Fitzroy, Australia, 3St Vincent's Hospital, Melbourne, Radiology, Fitzroy, Australia

P512: Results of interim analysis of a retrospective IGIBD study on adalimumab use in real practice in Italy: the REAL-life clinical effectiveness of ADAlimumab in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Pugliese1, M. Mendolaro2, R. D'Incà3, D. G. Ribaldone4, M. Principi5, C. Ricci6, E. Stasi7, M. L. Scribano8, G. Bodini9, S. Saibeni10, A. C. Privitera11, D. Simondi12, A. Armuzzi1, M. Daperno*2, Italian Group for Inflammatory Bowel Disease (IGIBD)1

1Fondazione Policlinico Gemelli IRCCS, Gastroenterology, Rome, Italy, 2Mauriziano Hospital, Gastroenterology Unit, Torino, Italy, 3Padua University, Gastroenterology Unit, Padua, Italy, 4Città della Scienza e della Salute, Gastroenterology Unit, Torino, Italy, 5Bari University, Gastroenterology Unit, Bari, Italy, 6Spedali Civili, Internal Medicine, Brescia, Italy, 7IRCCS De Bellis, Gastroenterology Unit, Castellana Grotte, Italy, 8S. Camillo-Forlanini Hospital, Gastroenterology Unit, Rome, Italy, 9Genova University Hospital, Gastroenterology Unit, Genova, Italy, 10Rho Hospital, Gastroenterology Unit, Rho, Italy, 11Cannizzaro Hospital, Gastroenterology, Catania, Italy, 12S. Croce and Carle Hospital, Gastroenterology Unit, Cuneo, Italy

P513: Performance of a rapid test for adalimumab monitoring vs. conventional ELISA in a routine laboratory setting

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Van Stappen*1, B. H. Roovers2, F. van Deurzen2, A. J. van Vuuren2

1R-Biopharm AG, Clinical Diagnostics, Darmstadt, Germany, 2Erasmus MC, Gastroenterology and Hepatology Diagnostic Laboratory, Rotterdam, The Netherlands

P514: Health Care Transition outcomes in inflammatory bowel disease: an international Delphi study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. van den Brink1, M. van Gaalen1, L. de Ridder1, J. Escher*1, J. van der Woude2

1Erasmus MC-Sophia Children’s Hospital, Paediatric Gastroenterology, Rotterdam, The Netherlands, 2Erasmus MC, Department of Gastroenterology, Rotterdam, The Netherlands

P515: Costs associated with the management of refractory complex perianal fistulas in patients with Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. D. Martín-Arranz*1, I. Pascual Migueláñez1, J. L. Marijuán1

1Hospital Universitario La Paz, Servicio de Ap. Digestivo, Madrid, Spain

P516: The use of first-line biologics in patients with ulcerative colitis in Norway from 2011 to 2016

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Anisdahl*1,2, S. Lirhus3, A. Medhus1, L. Buer1,2, H. O. Melberg3, B. Moum1,2, M. Lie Høivik1

1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 3University of Oslo, Institute of Health and Society, Oslo, Norway

P517: Activity assessment in ulcerative colitis: correlation analysis of endoscopic and histological scores

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Di Ruscio*1, A. Variola1, A. Geccherle1, S. Orlandi1, G. Lunardi2, P. Castelli3, G. Zamboni3, R. Riddell4

1IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar, Italy, 2IRCCS Sacro Cuore Don Calabria, Division of Medical Oncology, Negrar, Italy, 3IRCCS Sacro Cuore Don Calabria, Department of Pathology, Negrar, Italy, 4Mount Sinai Hospital University of Toronto, Department of Pathology and Laboratory Medicine, Toronto, Canada

P518: Cardiovascular Risk Factors in Adolescents with inflammatory bowel disease: A Cross-sectional Population-Based Study

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Ghersin*1, L. H. Katz2,3, S. Daher4, R. Shamir3,5, A. Assa3,5

1Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel, 2Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel, 3Tel Aviv University, The Sackler School of Medicine, Tel Aviv, Israel, 4IDF Medical Corps, Tel Hashomer, Israel, 5Schneider Children's Medical Center, Institute of Gastroenterology, Nutrition and Liver Disease, Petach Tikva, Israel